| HKND tracks an index that selects and weights US stocks, of any capitalization, based on socially responsible investment criteria. |
FUND BASICS
| Category |
US Equities |
| Fund Sponsor |
Humankind USA LLC |
| Website |
www.humankindfunds.com |
| Inception date |
Feb 24, 2021 |
| Assets (mns) |
$142 |
| Currency |
USD |
| Expense ratio |
11 bp |
| Distributions |
Annually |
FUND STRUCTURE
| Regulation |
Open-Ended Fund |
| Custodian |
|
| Weighting |
Principles-based |
| Index replication |
|
| Uses derivatives |
No |
| Options available |
No |
CONSTITUENT BREAKDOWN
| No. of constituents |
9 |
| Wgt avg mkt cap (mns) |
$0 |
| Large cap (>$10bn) |
86.1% |
| Mid cap ($2-10bn) |
9.5% |
| Small cap (<$2bn) |
3.7% |
| Developed mkts |
100.0% |
| Emerging mkts |
0.0% |
TOP TEN HOLDINGS
| ALBIREO PHARMA I -CVR |
0.0 % |
| NOVARTIS AG-CVR |
0.0 % |
| BRISTOL-MYER-CVR |
0.0 % |
| INHIBRX INC CVR |
0.0 % |
| OMNIAB -EARNOUT |
0.0 % |
| ABIOMED INC -CVR |
0.0 % |
| BLUEPRINT MED CVR |
0.0 % |
| ZIMMER BIOME-CVR |
0.0 % |
Total |
0.0 % |
TOP COUNTRY EXPOSURE
 |
|
0.0 % |
Standardized Annual Returns (thru December 31)
| Year-to-date |
1 year |
5 years |
10 years |
Since Incep. |
| 13.1% |
13.1% |
-- |
-- |
9.0% |
Market Correlations
| versus... |
Beta |
R-squared |
| S&P500 |
0.69 |
74% |
| MSCI EAFE |
0.77 |
64% |
| MSCI Emg. Mkts. |
0.65 |
52% |
Technical Indicators
| Recent close |
$35.36 |
| 30d moving avg. |
$35.18 |
| Annualized volatility |
11.8% |
| Short interest (ETF) |
0.0% |
| Relative strength (RSI) |
56 |
Liquidity measures
| Avg. volume (thou.) |
1 |
| Turnover |
0.0% |
| Bid/Ask (% of price) |
0.57% |
| ADV underlying (mns) |
$205,613 |
 |
There were no matches found with other funds under coverage. |
Content on this tab for subscribers only**
| |
2020 |
2021 |
2022 |
2023 |
2024 |
2025E |
2026E |
| Sales per share |
** |
** |
** |
** |
** |
** |
** |
| Earnings per share |
** |
** |
** |
** |
** |
** |
** |
Dividends per share  |
** |
** |
** |
** |
** |
** |
** |
| Book value per share |
** |
** |
** |
** |
** |
** |
** |
| Sales per share growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| EPS growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| Sales per share growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| EPS growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| Long term EPS growth est. |
**% |
|
Debt-to-equity |
**x |
| Asset turnover |
**% |
|
Assets-to-equity |
**x |
Revision activity*
|
| *Six months ago = 100 |
Compound annual growth rates
|
Content on this tab for subscribers only
| |
2024 |
2025E |
2026E |
| Price-to-sales |
** |
** |
** |
| Price-to-earnings |
** |
** |
** |
| Price-to-cash flow |
** |
** |
** |
| Price-to-growth |
** |
** |
** |
| Price-to-book value |
** |
** |
** |
| Yield |
** |
** |
** |
OVERWEIGHT |
| Above average appreciation potential. A rating of OVERWEIGHT is assigned to ETFs with ALTAR Scores in the 4th quintile (ranking higher than 60%-80%) of their category. Typically, funds in this category consist of stocks trading at attractive valuations and/or having above-average fundamentals. |
| Calculation of ALTAR Score™ |
| Avg. Return on Equity |
16.0 |
% |
| Divided by: Fwd. P/BV |
2.4 |
x |
| Less: Expense ratio |
11 |
bp |
| Equals: ALTAR Score |
6.5 |
% |
|
| More information on ALTAR Score™ |
|
|
|
Fundamentals